DDW News

DDW_Logo_2023_News-White

Experts to debate treatment of HBV, HCV during pregnancy

Nancy S. Reau, MD, FAASLD
Nancy S. Reau, MD, FAASLD

Tuesday’s AASLD Clinical Symposium Managing HBV and HCV in Pregnancy will feature a 25-minute debate about whether to treat hepatitis B (HBV) and hepatitis C (HCV) during pregnancy. The 90-minute session will also include two lectures and a case-based presentation.

Although there are incredibly effective therapies for viral hepatitis, disruption of maternal to child transmission (MTCT) remains an important aspect of prevention, said session co-moderator Nancy S. Reau, MD, FAASLD, professor in the department of internal medicine, division of digestive diseases and nutrition, at Rush Medical College, Chicago, IL.

“All GI/hepatologists are asked to assist maternal fetal medicine in the care of pregnant women with liver disease, and as the prevalence of HCV increases and screening guidelines change, we are certain to be faced with this clinical dilemma more often,” said Dr. Reau, who will moderate the session with Calvin Q. Pan, MD, MACP, FACG, FAASLD, clinical professor in the department of medicine at NYU Langone Health, New York.

Dr. Pan will open the symposium with a discussion of HBV management in pregnancy and an HBV case review. Tatyana Kushner, MD, MSCE, assistant professor of medicine in the division of liver diseases at the Icahn School of Medicine at Mount Sinai, New York, will discuss the prevalence and impact of HCV in women of child bearing age.

During the debate, Robert G. Gish, MD, FAASLD, adjunct professor of medicine at Stanford University in Palo Alto, CA, and also at the University of Nevada School of Medicine, Las Vegas, will argue in favor of HBV and HCV treatment during pregnancy. Dr. Gish is also medical director of the Hepatitis B Foundation in Doylestown, PA.

Paul Yien Kwo, MD, FAASLD, professor of medicine and director of hepatology at Stanford University, will argue against treatment.

“I hope at the conclusion we will equip the clinician to communicate the risk of MTCT and how to continue to monitor/treat both the mother and the child after delivery,” Dr. Reau said.

Please refer to the DDW Mobile App or the Program & Exhibits section for the time and location of this and other DDW® events.

Leave a Reply

Your email address will not be published.